Physician profile
Christopher B Watson
NPI 1134374424
$4,594.26
in general payments reported to CMS, 2019-2025
15 companies · $864 in 2025
The $864 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,611 · 2022: $1,211 · 2023: $156 · 2024: $752 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,545.12 | 2021-2025 | Proclaim |
| Medtronic, INC. | $551.55 | 2021-2025 | Inceptiv, Synchromedii, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.29 | 2021-2025 | Relistor |
| Nevro Corp. | $212.29 | 2021-2023 | Senza |
| Boston Scientific Corporation | $180.39 | 2022-2024 | |
| Si-Bone, INC. | $149.99 | 2025 | |
| Mml US, INC. | $129.12 | 2025 | Reactiv8 |
| Valinor Pharma, LLC | $93.18 | 2025 | Movantik |
| Abbvie INC. | $86.92 | 2021-2024 | |
| Lundbeck LLC | $71.90 | 2021-2023 | Vyepti |
| Collegium Pharmaceutical, INC. | $46.56 | 2023-2024 | Belbuca |
| Pfizer INC. | $39.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.53 | 2021 | |
| Radius Health, INC. | $17.63 | 2021 | |
| Ibsa Pharma INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.